New horizons in the development of antiepileptic drugs

Significant advances have been made in the treatment of epilepsy over the past decades. However, despite the development of various novel antiepileptic drugs, about one third of patients with epilepsy is resistant to current pharmacotherapies. Even in patients in whom pharmacotherapy is efficacious, current antiepileptic drugs do not seem to affect the progression or underlying natural history of epilepsy. Furthermore, there is currently no drug available which prevents the development of epilepsy, e.g. after head trauma. Thus, there are at least three important goals for the future. (1) Better understanding of processes leading to epilepsy, thus allowing to create therapies aimed at the prevention of epilepsy in patients at risk; (2) improved understanding of biological mechanisms of pharmacoresistance, allowing to develop drugs for reversal or prevention of resistance; and (3) development of disease-modifying therapies, inhibiting the progression of epilepsy. The ultimate goal would be a drug combining these three properties, thus resulting in a complete cure for epilepsy. In this review, the current status of antiepileptic therapies is critically assessed, and innovative approaches for future therapies are highlighted.

[1]  P. Worley,et al.  Homer Proteins Regulate Coupling of Group I Metabotropic Glutamate Receptors to N-Type Calcium and M-Type Potassium Channels , 2000, The Journal of Neuroscience.

[2]  Jerome Engel,et al.  Surgical treatment of the epilepsies , 1993 .

[3]  N. Upton.  Mechanisms of action of new antiepileptic drugs: rational design and serendipitous findings. , 1994, Trends in pharmacological sciences.

[4]  W Paulus,et al.  Transcranial magnetic stimulation: its current role in epilepsy research , 1998, Epilepsy Research.

[5]  J. McNamara.  Emerging insights into the genesis of epilepsy , 1999, Nature.

[6]  C. Bowden.  Bowden.vp:CorelVentura 7.0 , 2001 .

[7]  W. Löscher,et al.  Distribution of valproate across the interface between blood and cerebrospinal fluid , 1978, Neuropharmacology.

[8]  A. Sartorelli,et al.  Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[9]  M Pirmohamed,et al.  Genetic susceptibility to adverse drug reactions. , 2001, Trends in pharmacological sciences.

[10]  C. Besana,et al.  Partial Seizures Associated with Antiphospholipid Antibodies in Childhood , 1998, Neuropediatrics.

[11]  T. Maehara,et al.  Neuronal Disconnection for the Surgical Treatment of Pediatric Epilepsy , 2000, Epilepsia.

[12]  G. Regesta,et al.  Clinical aspects and biological bases of drug-resistant epilepsies , 1999, Epilepsy Research.

[13]  A. Schinkel,et al.  P-Glycoprotein, a gatekeeper in the blood-brain barrier. , 1999, Advanced drug delivery reviews.

[14]  C. Stafstrom,et al.  Recent Advances in the Genetics of Epilepsy: Insights from Human and Animal Studies , 1999, Epilepsia.

[15]  I. Scheffer,et al.  Genetics of the epilepsies , 2000, Current opinion in pediatrics.

[16]  Wolfgang Löscher,et al.  Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. , 2002, The Journal of pharmacology and experimental therapeutics.

[17]  W. Löscher,et al.  In Vivo Evidence for P‐Glycoprotein–Mediated Transport of Phenytoin at the Blood–Brain Barrier of Rats , 2001, Epilepsia.

[18]  B. Uthman.  Vagus nerve stimulation for seizures. , 2000, Archives of medical research.

[19]  Y. Schiller,et al.  Discontinuation of antiepileptic drugs after successful epilepsy surgery , 2000, Neurology.

[20]  E. Vermaas,et al.  In vitro cloning of complex mixtures of DNA on microbeads: physical separation of differentially expressed cDNAs. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[21]  O. Devinsky,et al.  Patients with refractory seizures. , 1999, The New England journal of medicine.

[22]  M. Knip,et al.  Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy , 2000, Neurology.

[23]  D. Coulter,et al.  Epilepsy-associated plasticity in gamma-aminobutyric acid receptor expression, function, and inhibitory synaptic properties. , 2001, International review of neurobiology.

[24]  R. Sapolsky,et al.  Sparing of neuronal function postseizure with gene therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[25]  J. Aarli,et al.  Epilepsy and the immune system. , 2000, Archives of neurology.

[26]  W. Bell,et al.  Surgical treatment of the epilepsies—Second edition , 1994 .

[27]  S. Sisodiya,et al.  Over-expression of P-glycoprotein in malformations of cortical development. , 1999, Neuroreport.

[28]  G. Vachtsevanos,et al.  Epileptic Seizures May Begin Hours in Advance of Clinical Onset A Report of Five Patients , 2001, Neuron.

[29]  Wolfgang Löscher,et al.  Animal models of intractable epilepsy , 1997, Progress in Neurobiology.

[30]  W. Löscher,et al.  Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation? , 1994, Epilepsy Research.

[31]  P. McCabe.  New anti-epileptic drugs for the 21st century , 2000, Expert opinion on pharmacotherapy.

[32]  Naomi Aronson,et al.  Ketogenic Diet for the Treatment of Refractory Epilepsy in Children: A Systematic Review of Efficacy , 2000, Pediatrics.

[33]  O. Steinlein,et al.  Ion channels and epilepsy in man and mouse. , 2000, Current opinion in genetics & development.

[34]  Rithy K. Roth,et al.  Gene expression analysis by massively parallel signature sequencing (MPSS) on microbead arrays , 2000, Nature Biotechnology.

[35]  I. Módy,et al.  The process of epileptogenesis: a pathophysiological approach , 2001, Current opinion in neurology.

[36]  R. Post.  Do the epilepsies, pain syndromes, and affective disorders share common kindling-like mechanisms? , 2002, Epilepsy Research.

[37]  T. Hernández.  Preventing post-traumatic epilepsy after brain injury: weighing the costs and benefits of anticonvulsant prophylaxis. , 1997, Trends in pharmacological sciences.

[38]  M Velasco,et al.  Subacute Electrical Stimulation of the Hippocampus Blocks Intractable Temporal Lobe Seizures and Paroxysmal EEG Activities , 2000, Epilepsia.

[39]  H. Lerche,et al.  Ion channels and epilepsy. , 2001, American journal of medical genetics.

[40]  L. Ratner,et al.  Multidrug resistance transporters and modulation , 2000, Current opinion in oncology.

[41]  A. Tobin,et al.  Conditionally Immortalized Cell Lines, Engineered to Produce and Release GABA, Modulate the Development of Behavioral Seizures , 2000, Experimental Neurology.

[42]  U. Brinkmann,et al.  ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. , 2001, Pharmacogenomics.

[43]  D. Miller,et al.  Expression of multidrug resistance-associated protein (MRP) in brain microvessel endothelial cells. , 1998, Biochemical and biophysical research communications.

[44]  W T Blume,et al.  A randomized, controlled trial of surgery for temporal-lobe epilepsy. , 2001, The New England journal of medicine.

[45]  M Thom,et al.  Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. , 2002, Brain : a journal of neurology.

[46]  W. Löscher,et al.  Responses to NMDA receptor antagonists altered by epileptogenesis. , 1991, Trends in pharmacological sciences.

[47]  A. Schinkel,et al.  P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. , 1996, The Journal of clinical investigation.

[48]  N. Barbaro,et al.  MDR1 Gene Expression in Brain of Patients with Medically Intractable Epilepsy , 1995, Epilepsia.

[49]  Gregory P. Lee,et al.  Withdrawal of antiepileptic medications following epilepsy surgery , 1991 .

[50]  T. Druley,et al.  From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance , 2001, Cellular and Molecular Life Sciences CMLS.

[51]  G. Holmes,et al.  Comparison of valproate and phenobarbital treatment after status epilepticus in rats , 1998, Neurology.

[52]  T. Pedley,et al.  Advances in the medical treatment of epilepsy. , 1998, Annual review of medicine.

[53]  R. MacPherson,et al.  The pharmacological basis of contemporary pain management. , 2000, Pharmacology & therapeutics.

[54]  M. Brodie.  Do we need any more new antiepileptic drugs? , 2001, Epilepsy Research.

[55]  D. Begley,et al.  Drug resistance in epilepsy: the role of the blood-brain barrier. , 2002, Novartis Foundation symposium.

[56]  J. Noebels,et al.  Single-gene models of epilepsy. , 1999, Advances in neurology.

[57]  T. Albertson,et al.  Neuropharmacology Methods in Epilepsy Research , 1998 .

[58]  T. Brown.  Primary care : epilepsy , 2001 .

[59]  A. Björklund,et al.  Cell replacement therapies for central nervous system disorders , 2000, Nature Neuroscience.

[60]  M Velasco,et al.  Acute and chronic electrical stimulation of the centromedian thalamic nucleus: modulation of reticulo-cortical systems and predictor factors for generalized seizure control. , 2000, Archives of medical research.

[61]  W. Frankel.  Detecting genes in new and old mouse models for epilepsy: a prospectus through the magnifying glass , 1999, Epilepsy Research.

[62]  W. Löscher,et al.  P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain , 2001, Neuroreport.

[63]  W. Löscher.  Animal Models of Epilepsy and Epileptic Seizures , 1999 .

[64]  J. Vignal,et al.  Correlation Between Interictal Regional Cerebral Blood Flow and Depth‐Recorded Interictal Spiking in Temporal Lobe Epilepsy , 1998, Epilepsia.

[65]  W. Löscher,et al.  New visions in the pharmacology of anticonvulsion. , 1998, European journal of pharmacology.

[66]  Holger Lehmann,et al.  Seizure suppression in kindling epilepsy by grafts of fetal GABAergic neurons in rat substantia nigra , 1998, Journal of neuroscience research.

[67]  W. Löscher,et al.  Delayed Sclerosis, Neuroprotection, and Limbic Epileptogenesis After Status Epilepticus in the Rat , 2002, Epilepsia.

[68]  B. Meldrum.  Identification and Preclinical Testing of Novel Antiepileptic Compounds , 1997, Epilepsia.

[69]  N. Déglon,et al.  Grafts of adenosine-releasing cells suppress seizures in kindling epilepsy , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[70]  W. Ong,et al.  Induction of P-glycoprotein expression in astrocytes following intracerebroventricular kainate injections , 1999, Experimental Brain Research.

[71]  J. Martinerie,et al.  Anticipation of epileptic seizures from standard EEG recordings , 2003, The Lancet.

[72]  W. Löscher,et al.  Multidrug resistance-associated protein is involved in the regulation of extracellular levels of phenytoin in the brain , 2001, Neuroreport.

[73]  R. Olsen,et al.  GABA receptor function and epilepsy. , 1999, Advances in neurology.

[74]  S. Aiken,et al.  Treatment of epilepsy: existing therapies and future developments. , 2000, Frontiers in bioscience : a journal and virtual library.

[75]  E. Ross.  The evolving role of antiepileptic drugs in treating neuropathic pain. , 2000, Neurology.

[76]  M. Thom,et al.  Multidrug-resistance protein 1 in focal cortical dysplasia , 2001, The Lancet.

[77]  P. Kwan,et al.  Early identification of refractory epilepsy. , 2000, The New England journal of medicine.

[78]  P. Worley,et al.  Homer: a link between neural activity and glutamate receptor function , 2000, Current Opinion in Neurobiology.

[79]  R. Post,et al.  Kindling: Separate vs. Shared Mechanisms in Affective Disorders and Epilepsy , 1998, Neuropsychobiology.

[80]  Martin Schoell,et al.  Diamondoids and oil are not forever , 1999, Nature.

[81]  M. Pirmohamed,et al.  Carbamazepine is not a substrate for P-glycoprotein. , 2001, British journal of clinical pharmacology.

[82]  J. McNamara,et al.  Antiepileptogenic effects of conventional anticonvulsants in the kindling model of epilepsy , 1991, Annals of neurology.

[83]  S. Huffel,et al.  Anticipation of epileptic seizures from standard EEG recordings , 2003, The Lancet.

[84]  W. Bingaman,et al.  Surgical treatment of epilepsy. , 2001, Neurologic clinics.

[85]  W. Hauser,et al.  Causes of epilepsy: contributions of the Rochester epidemiology project. , 1996, Mayo Clinic proceedings.